Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Lagere longkankermortaliteit door volume CT-screening bij hoogrisicopersonen
apr 2020 | Longoncologie